Evidence map›Paper›PMID 39372470›Full record

ArticleJACC. Advances2024

Mortality After Multivessel Revascularization in Patients With Diabetes and Acute Coronary Syndromes.

Lucas C Godoy, Michael E Farkouh, Peter C Austin, Baiju R Shah, Feng Qiu, Maneesh Sud, Jose C Nicolau, Stephen E Fremes, Rodolfo V Rocha, Derrick Y Tam and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lucas C GodoyPeter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
Michael E FarkouhPeter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
Peter C AustinICES, Toronto, Ontario, Canada.
Baiju R ShahICES, Toronto, Ontario, Canada.
Feng QiuICES, Toronto, Ontario, Canada.
Maneesh SudICES, Toronto, Ontario, Canada.
Jose C NicolauInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil.
Stephen E FremesInstitute of Health Policy Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Rodolfo V RochaPeter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
Derrick Y TamInstitute of Health Policy Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Karin H HumphriesFaculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Patrick R LawlerMcGill University Health Centre, McGill University, Montreal, Quebec, Canada.
Harindra C WijeysunderaICES, Toronto, Ontario, Canada.
Douglas S LeePeter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
Mario F L GaudinoDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York, USA.
Dennis T KoICES, Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The optimal revascularization strategy in patients with diabetes and multivessel disease in the setting of a non-ST-segment elevation myocardial infarction (NSTEMI) is unknown. Objectives: The purpose of this study was to compare all-cause mortality between coronary artery bypass grafting (CABG) and multivessel percutaneous coronary intervention (PCI) among patients with diabetes and NSTEMI. Methods: All patients with diabetes and multivessel disease admitted for NSTEMI in Ontario, Canada, between April 2009 and March 2020 were included. Those with previous CABG, PCI in the previous 90 days, or shock were excluded. The primary outcome was all-cause mortality. Propensity score matching was used to account for confounding. Patients who had a cardiac surgeon consultation and then received PCI were classified as being potentially ineligible for CABG. Results: The cohort included 4,649 CABG and 6,760 PCI patients (mean age: 67.8 ± 11.5 years; 70.4% males), resulting in 2,385 matched pairs. CABG was associated with reduced all-cause mortality compared to PCI over a median follow-up of 5.5 years (5-year estimates: 23.4% vs 26.5%; HR: 0.89; 95% CI: 0.80-0.98; Conclusions: While CABG was associated with reduced all-cause mortality compared to multivessel PCI in patients with diabetes and NSTEMI, CABG benefit was seen only against PCI patients potentially ineligible for CABG after receiving a preprocedure surgical consultation.

Indexed as

acute coronary syndromecoronary artery bypass graftingcoronary revascularizationdiabetespercutaneous coronary intervention

Identifiers

PMID39372470
PMCPMC11450960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.